Active Ingredient History

  • Now
Idebenone is a drug that was initially developed by Takeda Pharmaceutical Company for the treatment of Alzheimer's disease and other cognitive defects. This has been met with limited success. The Swiss company Santhera Pharmaceuticals has started to investigate it for the treatment of neuromuscular diseases. In 2010, early clinical trials for the treatment of Friedreich's ataxia and Duchenne muscular dystrophy have been completed. As of December 2013 the drug is not approved for these indications in North America or Europe. It is approved by the European Medicines Agency (EMA) for use in Leber's hereditary optic neuropathy (LHON) and was designated an orphan drug in 2007.   Wikipedia

  • SMILES: NS(=O)(=O)c1ccc(NCc2ccccc2)cc1
  • Mol. Mass: 262.33
  • ALogP: 1.95
  • ChEMBL Molecules:
More Chemistry
  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No
2-(10-hydroxydecyl)-5,6-dimethoxy-3-methyl-1,4-benzoquinone | 2-(10-hydroxydecyl)-5,6-dimethoxy-3-methylcyclohexa-2,5-diene-1,4-dione | 2-(10-hydroxydecyl)-5,6-dimethoxy-3-methyl-p-benzoquinone | 2,3-dimethoxy-5-methyl-6-(10'-hydroxydecyl)-1,4-benzoquinone | 6-(10-hydroxydecyl)-2,3-dimethoxy-5-methyl-1,4-benzoquinone | 6-(10-hydroxydecyl)-2,3-dimethoxy-5-methyl-p-benzoquinone | cv 2619 | cv-2619 | daruma | hydroxydecyl ubiquinone | idebenone | idébénone | noben | raxone


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue